|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Amati L, Pepe M, Passeri ME, Mastronardi
ML, Jirillo E and Covelli V: Toll-like receptor signaling
mechanisms involved in dendritic cell activation: potential
therapeutic control of T cell polarization. Curr Pharm Des.
12:4247–4254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chu CS, Boyer J, Schullery DS, et al:
Phase I/II randomized trial of dendritic cell vaccination with or
without cyclophosphamide for consolidation therapy of advanced
ovarian cancer in first or second remission. Cancer Immunol
Immunother. 61:629–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Triozzi PL, Khurram R, Aldrich WA, Walker
MJ, Kim JA and Jaynes S: Intratumoral injection of dendritic cells
derived in vitro in patients with metastatic cancer. Cancer.
89:2646–2654. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chakraborty G, Jain S, Behera R, et al:
The multifaceted roles of osteopontin in cell signaling, tumor
progression and angiogenesis. Curr Mol Med. 6:819–830. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bulfone-Paus S and Paus R: Osteopontin as
a new player in mast cell biology. Eur J Immunol. 38:338–341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pagano PJ and Haurani MJ: Vascular cell
locomotion: osteopontin, NADPH oxidase, and matrix
metalloproteinase-9. Circ Res. 98:1453–1455. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan SA, Cook AC, Kappil M, et al:
Enhanced cell surface CD44 variant (v6, v9) expression by
osteopontin in breast cancer epithelial cells facilitates tumor
cell migration: novel post-transcriptional, post-translational
regulation. Clin Exp Metastasis. 22:663–673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YJ, Wei YY, Chen HT, et al:
Osteopontin increases migration and MMP-9 up-regulation via
alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in
human chondrosarcoma cells. J Cell Physiol. 221:98–108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Desai B, Ma T, Zhu J and Chellaiah MA:
Characterization of the expression of variant and standard CD44 in
prostate cancer cells: identification of the possible molecular
mechanism of CD44/MMP9 complex formation on the cell surface. J
Cell Biochem. 108:272–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang G, Zhang Y, Wu J, et al: Osteopontin
regulates growth and migration of human nasopharyngeal cancer
cells. Mol Med Rep. 4:1169–1173. 2011.PubMed/NCBI
|
|
12
|
Schulz G, Renkl AC, Seier A, Liaw L and
Weiss JM: Regulated osteopontin expression by dendritic cells
decisively affects their migratory capacity. J Invest Dermatol.
128:2541–2544. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Visintin I, Feng Z, Longton G, et al:
Diagnostic markers for early detection of ovarian cancer. Clin
Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bao LH, Sakaguchi H, Fujimoto J and Tamaya
T: Osteopontin in metastatic lesions as a prognostic marker in
ovarian cancers. J Biomed Sci. 14:373–381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Zhang HQ, Zhu GH, et al: A novel
mono-carbonyl analogue of curcumin induces apoptosis in ovarian
carcinoma cells via endoplasmic reticulum stress and reactive
oxygen species production. Mol Med Rep. 5:739–744. 2012.
|
|
16
|
Selvendiran K, Ahmed S, Dayton A, et al:
HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian
carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Cancer Biol Ther. 12:837–845. 2011. View Article : Google Scholar
|
|
17
|
Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y
and Sonobe T: Beneficial effects of curcumin on antitumor activity
and adverse reactions of doxorubicin. Int J Pharm. 432:42–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo F, Song X, Zhang Y and Chu Y: Low-dose
curcumin leads to the inhibition of tumor growth via enhancing
CTL-mediated antitumor immunity. Int Immunopharmacol. 11:1234–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhattacharyya S, Md Sakib Hossain D,
Mohanty S, et al: Curcumin reverses T cell-mediated adaptive immune
dysfunctions in tumor-bearing hosts. Cell Mol Immunol. 7:306–315.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badisa RB, Tzakou O, Couladis M and
Pilarinou E: Cytotoxic activities of some Greek Labiatae herbs.
Phytother Res. 17:472–476. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia L, Zheng G, Zhou H, et al: The
application of BPS in the preparing of anti-metastasis therapies.
P.R. China Patent CN1498625. Filed, November 8, 2002; Issued, May
26, 2004 (In Chinese).
|
|
22
|
Renkl AC, Wussler J, Ahrens T, et al:
Osteopontin functionally activates dendritic cells and induces
their differentiation toward a Th1-polarizing phenotype. Blood.
106:946–955. 2005. View Article : Google Scholar
|
|
23
|
Ji C, Cao C, Lu S, et al: Curcumin
attenuates EGF-induced AQP3 up-regulation and cell migration in
human ovarian cancer cells. Cancer Chemother Pharmacol. 62:857–865.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seo JH, Jeong KJ, Oh WJ, et al:
Lysophosphatidic acid induces STAT3 phosphorylation and ovarian
cancer cell motility: their inhibition by curcumin. Cancer lett.
288:50–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shirley SA, Montpetit AJ, Lockey RF and
Mohapatra SS: Curcumin prevents human dendritic cell response to
immune stimulants. Biochem Biophys Res Commun. 374:431–436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tilli TM, Franco VF, Robbs BK, et al:
Osteopontin-c splicing isoform contributes to ovarian cancer
progression. Mol Cancer Res. 9:280–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang W, Yang HC, Wang Q, et al: Clinical
value of combined detection of serum matrix metalloproteinase-9,
heparanase, and cathepsin for determining ovarian cancer invasion
and metastasis. Anticancer Res. 31:3423–3428. 2011.
|
|
28
|
Lin YG, Kunnumakkara AB, Nair A, et al:
Curcumin inhibits tumor growth and angiogenesis in ovarian
carcinoma by targeting the nuclear factor-kappaB pathway. Clin
Cancer Res. 13:3423–3430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watson JL, Greenshields A, Hill R, et al:
Curcumin-induced apoptosis in ovarian carcinoma cells is
p53-independent and involves p38 mitogen-activated protein kinase
activation and downregulation of Bcl-2 and survivin expression and
Akt signaling. Mol Carcinog. 49:13–24. 2010.
|
|
30
|
Ganta S, Devalapally H and Amiji M:
Curcumin enhances oral bioavailability and anti-tumor therapeutic
efficacy of paclitaxel upon administration in nanoemulsion
formulation. J Pharm Sci. 99:4630–4641. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rogers NM, Kireta S and Coates PT:
Curcumin induces maturation-arrested dendritic cells that expand
regulatory T cells in vitro and in vivo. Clin Exp Immunol.
162:460–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cong Y, Wang L, Konrad A, Schoeb T and
Elson CO: Curcumin induces the tolerogenic dendritic cell that
promotes differentiation of intestine-protective regulatory T
cells. Eur J Immunol. 39:3134–3146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Orian-Rousseau V: CD44, a therapeutic
target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Samanna V, Wei H, Ego-Osuala D and
Chellaiah MA: Alpha-V-dependent outside-in signaling is required
for the regulation of CD44 surface expression, MMP-2 secretion, and
cell migration by osteopontin in human melanoma cells. Exp Cell
Res. 312:2214–2230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jijiwa M, Demir H, Gupta S, et al: CD44v6
regulates growth of brain tumor stem cells partially through the
AKT-mediated pathway. PloS One. 6:e242172011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chagan-Yasutan H, Tsukasaki K, Takahashi
Y, et al: Involvement of osteopontin and its signaling molecule
CD44 in clinicopathological features of adult T cell leukemia. Leuk
Res. 35:1484–1490. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Philip S and Kundu GC: Osteopontin induces
nuclear factor kappa B-mediated promatrix metalloproteinase-2
activation through I kappa B alpha /IKK signaling pathways, and
curcumin (diferulolylmethane) down-regulates these pathways. J Biol
Chem. 278:14487–14497. 2003. View Article : Google Scholar
|
|
38
|
Bagnoli F, Oliveira VM, Silva MA, Taromaru
GC, Rinaldi JF and Aoki T: The interaction between aromatase,
metalloproteinase 2,9 and CD44 in breast cancer. Rev Assoc Med
Bras. 56:472–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu Q and Stamenkovic I: Cell
surface-localized matrix metalloproteinase-9 proteolytically
activates TGF-beta and promotes tumor invasion and angiogenesis.
Genes Dev. 14:163–176. 2000.PubMed/NCBI
|
